IDIOTYPE VACCINATION AFTER BMT FOR B CELL MALIGNANCIES

这项试验评估了研制一种新型疫苗的可行性。 激发抗肿瘤免疫反应，提供治疗益处 适用于已完成大剂量治疗的B细胞恶性肿瘤患者 干细胞拯救疗法。每月的疫苗由两种疫苗组成 自体树突状细胞(专业抗原)治疗 呈现细胞)通过失语症收集，用个体化的脉冲 以肿瘤独特型为靶点，回输，然后再注射5剂 在皮下注射的ISAF佐剂中，独特型与KLH偶联。 2例非霍奇金淋巴瘤和9例多发性 骨髓瘤已经完成了疫苗接种疗程。另外七个 患者正在接种疫苗，还有几名患者正在接种疫苗 计划很快就会开始。树突状细胞的收集已经被 足够的，而且重新输血已经很好地容忍了NeXT 没有毒性。最初的两名患者已经出现了可测量的T-T- 独特型暴露后的细胞增殖反应提示 具有抗肿瘤作用的可能性。一名患者产生了一种 可测量的体液抗独特型抗体。这些回应一直是 在完成大剂量治疗后的六个月内被确认。

This trial evaluates the feasibility of formulating a novel vaccine to stimulate anti-tumor immune responses and provide therapeutic benefit for patients with B cell malignancies who have completed high dose therapy with stem cell rescue. The monthly vaccines consists of two treatments with autologous dendritic cells (professional antigen presenting cells) collected by apharesis, pulsed with individualized tumor idiotype as target and reinfused, followed by five doses of idiotype coupled to KLH in an ISAF adjuvant injected subcutaneously. Two patients with non-Hodgkin's lymphoma and nine patients with multiple myeloma have completed the vaccination course. An additional seven patients are in the process of being vaccinated and several more are scheduled to start soon. The dendritic cell collections have been adequate and the reinfusions have been very well tolerated with next to no toxicity. Two of the initial patients have developed measureable T- cell proliferative responses after exposure to idiotype suggesting the possibility of anti-tumor effect. One patient has produced a measureable humoral anti-idiotype antibodies. These reponses have been identified within six months of completing the high dose therapy.